Palatin Technologies, Inc. (PTN)
USD 0.77
(-0.84%)
USD 0.77
(-0.84%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 | 10.74 Million USD | -40.12% |
| 2023 | 17.93 Million USD | -50.27% |
| 2022 | 36.07 Million USD | -46.4% |
| 2021 | 67.29 Million USD | -20.88% |
| 2020 | 85.05 Million USD | -18.79% |
| 2019 | 104.73 Million USD | 168.44% |
| 2018 | 39.01 Million USD | -31.35% |
| 2017 | 56.83 Million USD | 414.25% |
| 2016 | 11.05 Million USD | -62.5% |
| 2015 | 29.47 Million USD | 134.69% |
| 2014 | 12.55 Million USD | -49.91% |
| 2013 | 25.07 Million USD | 366.02% |
| 2012 | 5.38 Million USD | -74.59% |
| 2011 | 21.17 Million USD | 70.9% |
| 2010 | 12.38 Million USD | -6.14% |
| 2009 | 13.19 Million USD | -30.98% |
| 2008 | 19.12 Million USD | -55.3% |
| 2007 | 42.78 Million USD | 6.83% |
| 2006 | 40.04 Million USD | 13.88% |
| 2005 | 35.16 Million USD | 44.25% |
| 2004 | 24.37 Million USD | 7.3% |
| 2003 | 22.72 Million USD | 83.85% |
| 2002 | 12.35 Million USD | -13.24% |
| 2001 | 14.24 Million USD | 60.31% |
| 2000 | 8.88 Million USD | 89.05% |
| 1999 | 4.7 Million USD | -27.69% |
| 1998 | 6.5 Million USD | -53.9% |
| 1997 | 14.1 Million USD | 100.25% |
| 1996 | 7.04 Million USD | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q3 | 11.4 Million USD | -15.85% |
| 2024 Q2 | 13.55 Million USD | 20.51% |
| 2024 Q1 | 11.24 Million USD | -37.3% |
| 2024 Q4 | 10.74 Million USD | -5.82% |
| 2023 Q2 | 31.97 Million USD | 15.68% |
| 2023 Q3 | 25.6 Million USD | -19.91% |
| 2023 FY | 17.93 Million USD | -50.27% |
| 2023 Q1 | 27.64 Million USD | -23.37% |
| 2023 Q4 | 17.93 Million USD | -29.95% |
| 2022 Q1 | 59.73 Million USD | -11.24% |
| 2022 Q2 | 52.99 Million USD | -11.28% |
| 2022 Q3 | 43.81 Million USD | -17.32% |
| 2022 FY | 36.07 Million USD | -46.4% |
| 2022 Q4 | 36.07 Million USD | -17.68% |
| 2021 Q4 | 67.29 Million USD | -16.79% |
| 2021 Q1 | 101.15 Million USD | 18.93% |
| 2021 Q2 | 86.77 Million USD | -14.22% |
| 2021 FY | 67.29 Million USD | -20.88% |
| 2021 Q3 | 80.87 Million USD | -6.81% |
| 2020 Q4 | 85.05 Million USD | -5.55% |
| 2020 Q1 | 97.97 Million USD | -6.46% |
| 2020 FY | 85.05 Million USD | -18.79% |
| 2020 Q3 | 90.05 Million USD | -2.91% |
| 2020 Q2 | 92.75 Million USD | -5.33% |
| 2019 Q4 | 104.73 Million USD | 398.59% |
| 2019 Q3 | 21 Million USD | -18.16% |
| 2019 Q2 | 25.66 Million USD | -23.68% |
| 2019 Q1 | 33.63 Million USD | -13.8% |
| 2019 FY | 104.73 Million USD | 168.44% |
| 2018 FY | 39.01 Million USD | -31.35% |
| 2018 Q2 | 36.98 Million USD | -26.82% |
| 2018 Q1 | 50.53 Million USD | -11.08% |
| 2018 Q4 | 39.01 Million USD | 43.66% |
| 2018 Q3 | 27.15 Million USD | -26.56% |
| 2017 Q2 | 14.46 Million USD | 26.91% |
| 2017 FY | 56.83 Million USD | 414.25% |
| 2017 Q3 | 61.28 Million USD | 323.57% |
| 2017 Q1 | 11.4 Million USD | 3.16% |
| 2017 Q4 | 56.83 Million USD | -7.26% |
| 2016 Q4 | 11.05 Million USD | -55.64% |
| 2016 FY | 11.05 Million USD | -62.5% |
| 2016 Q1 | 49.68 Million USD | 68.57% |
| 2016 Q2 | 35.39 Million USD | -28.76% |
| 2016 Q3 | 24.91 Million USD | -29.61% |
| 2015 Q2 | 47.59 Million USD | 157.92% |
| 2015 FY | 29.47 Million USD | 134.69% |
| 2015 Q1 | 18.45 Million USD | 46.92% |
| 2015 Q3 | 39.02 Million USD | -17.99% |
| 2015 Q4 | 29.47 Million USD | -24.48% |
| 2014 Q3 | 17.37 Million USD | -7.35% |
| 2014 FY | 12.55 Million USD | -49.91% |
| 2014 Q2 | 18.75 Million USD | -18.06% |
| 2014 Q1 | 22.89 Million USD | -8.71% |
| 2014 Q4 | 12.55 Million USD | -27.73% |
| 2013 Q3 | 30.38 Million USD | -9.49% |
| 2013 Q4 | 25.07 Million USD | -17.49% |
| 2013 FY | 25.07 Million USD | 366.02% |
| 2013 Q1 | 34.7 Million USD | 544.98% |
| 2013 Q2 | 33.57 Million USD | -3.24% |
| 2012 Q2 | 14.99 Million USD | -10.97% |
| 2012 Q3 | 10.45 Million USD | -30.29% |
| 2012 Q4 | 5.38 Million USD | -48.53% |
| 2012 FY | 5.38 Million USD | -74.59% |
| 2012 Q1 | 16.84 Million USD | -20.45% |
| 2011 Q3 | 24.68 Million USD | 281.57% |
| 2011 Q4 | 21.17 Million USD | -14.24% |
| 2011 FY | 21.17 Million USD | 70.9% |
| 2011 Q1 | 8.38 Million USD | -32.29% |
| 2011 Q2 | 6.46 Million USD | -22.87% |
| 2010 FY | 12.38 Million USD | -6.14% |
| 2010 Q4 | 12.38 Million USD | -14.88% |
| 2010 Q3 | 14.55 Million USD | 7.25% |
| 2010 Q2 | 13.57 Million USD | -11.4% |
| 2010 Q1 | 15.31 Million USD | 16.03% |
| 2009 Q3 | 16.93 Million USD | 0.53% |
| 2009 FY | 13.19 Million USD | -30.98% |
| 2009 Q4 | 13.19 Million USD | -22.05% |
| 2009 Q2 | 16.84 Million USD | 17.23% |
| 2009 Q1 | 14.36 Million USD | -24.87% |
| 2008 Q4 | 19.12 Million USD | -23.09% |
| 2008 Q1 | 34.48 Million USD | -19.4% |
| 2008 FY | 19.12 Million USD | -55.3% |
| 2008 Q2 | 30.13 Million USD | -12.62% |
| 2008 Q3 | 24.86 Million USD | -17.47% |
| 2007 Q1 | 29.96 Million USD | -25.17% |
| 2007 FY | 42.78 Million USD | 6.83% |
| 2007 Q3 | 51.82 Million USD | 110.08% |
| 2007 Q4 | 42.78 Million USD | -17.45% |
| 2007 Q2 | 24.66 Million USD | -17.68% |
| 2006 Q3 | 26.21 Million USD | -14.88% |
| 2006 Q4 | 40.04 Million USD | 52.78% |
| 2006 FY | 40.04 Million USD | 13.88% |
| 2006 Q2 | 30.79 Million USD | -19.54% |
| 2006 Q1 | 38.27 Million USD | 8.84% |
| 2005 Q4 | 35.16 Million USD | -7.28% |
| 2005 Q3 | 37.92 Million USD | -3.94% |
| 2005 Q2 | 39.48 Million USD | -4.89% |
| 2005 Q1 | 41.51 Million USD | 70.29% |
| 2005 FY | 35.16 Million USD | 44.25% |
| 2004 FY | 24.37 Million USD | 7.3% |
| 2004 Q4 | 24.37 Million USD | -21.24% |
| 2004 Q3 | 30.95 Million USD | 99.37% |
| 2004 Q1 | 19.68 Million USD | -13.35% |
| 2004 Q2 | 15.52 Million USD | -21.13% |
| 2003 Q2 | 16.01 Million USD | 57.49% |
| 2003 Q1 | 10.16 Million USD | -17.71% |
| 2003 FY | 22.72 Million USD | 83.85% |
| 2003 Q3 | 30.06 Million USD | 87.72% |
| 2003 Q4 | 22.72 Million USD | -24.43% |
| 2002 Q2 | 17.43 Million USD | 65.31% |
| 2002 Q1 | 10.54 Million USD | -25.96% |
| 2002 Q3 | 13.69 Million USD | -21.46% |
| 2002 FY | 12.35 Million USD | -13.24% |
| 2002 Q4 | 12.35 Million USD | -9.74% |
| 2001 Q2 | 20.15 Million USD | 18.49% |
| 2001 Q4 | 14.24 Million USD | -18.18% |
| 2001 Q3 | 17.4 Million USD | -13.64% |
| 2001 FY | 14.24 Million USD | 60.31% |
| 2001 Q1 | 17.01 Million USD | 91.48% |
| 2000 Q1 | 14.6 Million USD | 210.64% |
| 2000 FY | 8.88 Million USD | 89.05% |
| 2000 Q2 | 12.7 Million USD | -13.01% |
| 2000 Q3 | 10.4 Million USD | -18.1% |
| 2000 Q4 | 8.88 Million USD | -14.57% |
| 1999 Q1 | 5.5 Million USD | -15.38% |
| 1999 FY | 4.7 Million USD | -27.69% |
| 1999 Q4 | 4.7 Million USD | -16.07% |
| 1999 Q3 | 5.6 Million USD | 43.59% |
| 1999 Q2 | 3.9 Million USD | -29.09% |
| 1998 Q3 | 7.3 Million USD | -19.78% |
| 1998 FY | 6.5 Million USD | -53.9% |
| 1998 Q1 | 11.7 Million USD | -17.02% |
| 1998 Q2 | 9.1 Million USD | -22.22% |
| 1998 Q4 | 6.5 Million USD | -10.96% |
| 1997 Q1 | 4.7 Million USD | -32.86% |
| 1997 Q2 | 3.3 Million USD | -29.79% |
| 1997 Q4 | 14.1 Million USD | 156.36% |
| 1997 Q3 | 5.5 Million USD | 66.67% |
| 1997 FY | 14.1 Million USD | 100.25% |
| 1996 FY | 7.04 Million USD | 0.0% |
| 1996 Q4 | 7 Million USD | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| AIM ImmunoTech Inc. | 19.38 Million USD | 44.573% |
| Ampio Pharmaceuticals, Inc. | 5.73 Million USD | -87.278% |
| Armata Pharmaceuticals, Inc. | 109.96 Million USD | 90.231% |
| Actinium Pharmaceuticals, Inc. | 81.44 Million USD | 86.81% |
| Azitra, Inc. | 5.11 Million USD | -109.995% |
| Can-Fite BioPharma Ltd. | 9.98 Million USD | -7.541% |
| Chromocell Therapeutics Corporation | 96.39 Thousand USD | -11044.47% |
| Calidi Biotherapeutics, Inc. | 10.01 Million USD | -7.219% |
| CEL-SCI Corporation | 30.52 Million USD | 64.812% |
| iBio, Inc. | 28.73 Million USD | 62.615% |
| Lineage Cell Therapeutics, Inc. | 101.01 Million USD | 89.366% |
| MAIA Biotechnology, Inc. | 7.56 Million USD | -41.965% |
| Matinas BioPharma Holdings, Inc. | 65.57 Million USD | 83.619% |
| Navidea Biopharmaceuticals, Inc. | 4.37 Million USD | -145.728% |
| NovaBay Pharmaceuticals, Inc. | 9.03 Million USD | -18.909% |
| NanoViricides, Inc. | 12.82 Million USD | 16.226% |
| Oragenics, Inc. | 4.96 Million USD | -116.302% |
| BiomX Inc. | 58.15 Million USD | 81.529% |
| BiomX Inc. | 58.15 Million USD | 81.529% |
| Protalix BioTherapeutics, Inc. | 84.43 Million USD | 87.277% |
| Scorpius Holdings, Inc. | 51.03 Million USD | 78.952% |